Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Singh M, Rebordosa C, Bernholz J, Sharma N. Epidemiology and genetics of cystic fibrosis in Asia: in preparation for the next-generation treatments. Respirology. 2015 Nov 6;20(8):1172-81. doi: 10.1111/resp.12656
Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011 Nov;16(8):1235-40. doi: 10.1111/j.1440-1843.2011.02030.x
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.
Holmes SJ, McKenna SP, Doward LC, Hunt SM, Shalet SM. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrinology and metabolism. 1995 Jan 1;2(1):63-9.